In a significant stride toward the personalization of dermatological oncology, Dutch biotechnology firm SkylineDX has received US Food and Drug Administration (FDA) Breakthrough Device Designation for its Merlin clinicopathologic gene expression profile (CP-GEP) test. Designed to assess metastatic risk in patients diagnosed with early-stage cutaneous melanoma, this diagnostic tool promises to shift the paradigm of surgical and therapeutic decision-making for some of the most challenging patient cohorts.
The designation marks a pivotal moment for SkylineDX, which developed the technology in close collaboration with the Mayo Clinic. By integrating traditional clinicopathologic variables with advanced gene expression data into a proprietary algorithm, the Merlin test provides a stratified risk assessment—categorizing patients into high- or low-risk groups for metastasis. This granular insight enables clinicians to tailor treatment pathways, moving away from a “one-size-fits-all” approach to surgical intervention.
The Science of Stratification: How Merlin Works
Cutaneous melanoma, particularly in its early stages, presents a significant clinical conundrum. While many patients have a favorable prognosis following initial excision, a subset of these individuals remains at risk for occult metastasis. Traditionally, staging has relied heavily on clinical factors such as tumor thickness (Breslow depth) and ulceration status. However, these metrics alone often fail to capture the underlying molecular biology driving disease progression.
The Merlin CP-GEP test fills this diagnostic void. By analyzing the molecular signature of the tumor and combining this with validated clinical variables, the test generates a comprehensive risk profile. For patients categorized as high-risk, the clinical team may opt for more aggressive staging procedures, such as sentinel lymph node biopsies (SLNB), or increased surveillance. Conversely, patients identified as low-risk may avoid unnecessary, invasive procedures, thereby reducing patient morbidity and healthcare costs.
Chronology of Development and Regulatory Milestones
The journey of the Merlin test from the research bench to the clinical frontline reflects the evolving landscape of diagnostic medicine.
- Initial Research and Validation: Developed through a long-term partnership with the Mayo Clinic, the algorithm underwent extensive retrospective validation to ensure its predictive accuracy regarding metastatic potential.
- Clinical Adoption: Prior to the recent FDA designation, the Merlin test had already established a footprint as a Laboratory Developed Test (LDT), currently available to providers in the United States and Europe.
- NCCN Recognition: A major validation of the test’s clinical utility came when the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology included Merlin as a recommended predictive GEP test. This inclusion specifically supports its use in assessing metastatic risk for patients with T1b and T2a melanoma, solidifying its place in standard clinical workflows.
- FDA Breakthrough Designation (Current): The recent awarding of the FDA’s Breakthrough Device Designation serves as a catalyst to accelerate the review process for full commercialization, providing a streamlined regulatory pathway that prioritizes the delivery of this technology to patients.
Supporting Data and Clinical Utility
The power of the Merlin test lies in its dual-modality approach. Many existing diagnostic tests focus exclusively on either genomic expression or clinicopathologic features. SkylineDX’s decision to integrate both into a single, unified algorithm is supported by data suggesting that such an approach significantly improves the Area Under the Curve (AUC) for predicting metastasis compared to single-variable models.
For oncologists, this data is actionable. Clinical utility studies have demonstrated that when clinicians are provided with a Merlin risk score, their management plans change in a significant percentage of cases. By identifying patients who are at a lower risk for nodal involvement, the test serves as a "rule-out" tool that prevents the overtreatment of early-stage disease. Simultaneously, for high-risk patients, it serves as a "rule-in" tool, justifying the immediate allocation of surgical resources.
Official Perspectives: A Commitment to Patient-Centred Care
The announcement of the FDA designation has been met with optimism from the leadership at SkylineDX, who view the regulatory nod as a validation of their patient-centric vision.
“Breakthrough device designation underscores the potential of Merlin CP-GEP to advance personalised melanoma care and support more informed, patient-centred treatment decisions,” said Dharminder Chahal, CEO of SkylineDX. “Patients deserve access to the best available tools supported by rigorous clinical evidence and recognised in clinical practice guidelines.”
Chahal’s sentiment echoes a broader industry push toward "precision staging." By ensuring that clinical interventions are proportional to the actual biological risk of the tumor, SkylineDX aims to reduce the physical and psychological burden on patients who might otherwise undergo unnecessary procedures, while ensuring those with aggressive tumors receive timely care.
The Broader Context: Navigating the LDT Regulatory Landscape
The success of the Merlin test occurs against the backdrop of a highly volatile regulatory environment for Laboratory Developed Tests (LDTs) in the United States. For decades, LDTs have been subject to a more lenient oversight framework under the Clinical Laboratory Improvement Amendments (CLIA).
The Rise and Fall of the FDA’s Final Rule
In April 2025, the diagnostic industry was shaken by the FDA’s attempt to formalize the regulation of LDTs as medical devices. The move was intended to ensure that all diagnostic tests met stringent pre-market approval standards. However, the rule faced immediate legal challenges. In a landmark decision, a Texas court struck down the FDA’s Final Rule, and by September 2025, the agency confirmed it would not challenge the ruling, effectively shelving the plan.
The Legislative Pivot: The "Enhancing CLIA Act"
The regulatory pendulum is now swinging toward a legislative solution rather than executive rulemaking. In May 2026, Congressman Neal Dunn introduced the Enhancing Clinical Laboratory Innovation and Access Act (Enhancing CLIA Act). This bill seeks to modernize the oversight of diagnostic testing by updating the CLIA program.
Unlike the FDA’s previous mandate, which was criticized as "burdensome" and "stifling to innovation," the Dunn bill has garnered support from major industry bodies, including the American Clinical Laboratory Association (ACLA).
Susan Van Meter, President of the ACLA, praised the legislation, noting: “ACLA appreciates Representative Neal Dunn’s thoughtful approach to updating the CLIA programme to ensure that the regulatory framework for clinical laboratories keeps pace with innovations… and increases transparency in LDTs for providers and patients.”
Implications for the Future of Diagnostics
The trajectory of the Merlin test serves as a case study for the future of diagnostics. As we move further into an era of genomic medicine, the ability to synthesize complex biological data into simple, actionable insights will be the primary driver of value in healthcare.
1. Clinical Efficiency
The integration of Merlin into standard care pathways suggests a future where surgical oncology is more efficient. By optimizing the use of sentinel lymph node biopsies, hospitals can reduce waiting times for surgical suites and improve the quality of life for patients who are spared unnecessary surgeries.
2. Economic Impact
While the initial cost of diagnostic testing is a factor, the long-term economic impact of accurate risk stratification is overwhelmingly positive. Reducing the number of surgical complications and unnecessary hospitalizations associated with mis-staged melanoma represents a significant cost saving for private and public insurers alike.
3. The New Regulatory Standard
With the Enhancing CLIA Act gaining momentum, the path cleared by the FDA’s Breakthrough Designation for Merlin may become the "gold standard" for future diagnostic launches. By engaging with the FDA early, companies like SkylineDX are demonstrating that even in a changing regulatory landscape, there is a clear pathway for evidence-based innovation to reach the bedside.
Conclusion
The FDA’s Breakthrough Device Designation for the Merlin CP-GEP test is more than a regulatory milestone; it is a signal of the maturation of precision oncology. By successfully bridging the gap between molecular diagnostics and clinical practice, SkylineDX is providing clinicians with the tools necessary to navigate the complexities of melanoma. As the legislative landscape surrounding LDTs continues to evolve, the focus on patient outcomes, evidence-based guidelines, and innovation—as exemplified by the Merlin test—will remain the guiding principles for the diagnostic industry.
For the thousands of patients diagnosed with early-stage cutaneous melanoma each year, this development offers a clearer path forward, ensuring that the care they receive is as unique as their own genetic profile.
About the Author
